KR20230107309A - 항-gdf15 항체 및 암 치료용 투여 용법 - Google Patents

항-gdf15 항체 및 암 치료용 투여 용법 Download PDF

Info

Publication number
KR20230107309A
KR20230107309A KR1020237019624A KR20237019624A KR20230107309A KR 20230107309 A KR20230107309 A KR 20230107309A KR 1020237019624 A KR1020237019624 A KR 1020237019624A KR 20237019624 A KR20237019624 A KR 20237019624A KR 20230107309 A KR20230107309 A KR 20230107309A
Authority
KR
South Korea
Prior art keywords
antibody
cancer
amino acid
gdf
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237019624A
Other languages
English (en)
Korean (ko)
Inventor
오이겐 레오
마르쿠스 하케
요에르그 위츠휘센
브룬 비르지니 르
수잔 요에르그
Original Assignee
카탈임 게엠베하
율리우스-막시밀리안스 우니버지태트 뷔르츠부르크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카탈임 게엠베하, 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 filed Critical 카탈임 게엠베하
Publication of KR20230107309A publication Critical patent/KR20230107309A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237019624A 2020-11-10 2021-11-10 항-gdf15 항체 및 암 치료용 투여 용법 Pending KR20230107309A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20206801.1 2020-11-10
EP20206801 2020-11-10
EP21175107.8 2021-05-20
EP21175107 2021-05-20
EP21196910.0 2021-09-15
EP21196910 2021-09-15
PCT/EP2021/081236 WO2022101263A1 (en) 2020-11-10 2021-11-10 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20230107309A true KR20230107309A (ko) 2023-07-14

Family

ID=78500639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019624A Pending KR20230107309A (ko) 2020-11-10 2021-11-10 항-gdf15 항체 및 암 치료용 투여 용법

Country Status (8)

Country Link
US (3) US20240043517A1 (https=)
EP (1) EP4243928B1 (https=)
JP (1) JP2023548430A (https=)
KR (1) KR20230107309A (https=)
AU (1) AU2021376864A1 (https=)
CA (1) CA3200687A1 (https=)
IL (1) IL302646A (https=)
WO (1) WO2022101263A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111636A1 (ja) * 2019-12-06 2021-06-10 大塚製薬株式会社 抗ｇｄｆ１５抗体
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
IL319354A (en) 2022-09-08 2025-05-01 Catalym Gmbh Anti-GDF15 antibody used in combination therapy of specific patient groups and dosing regimen for cancer treatment
WO2024126808A1 (en) 2022-12-16 2024-06-20 Catalym Gmbh Anti-gdf 15 antibody for neoadjuvant therapy of cancer
CN116462757A (zh) 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
EP1734986B1 (en) 2004-04-13 2015-11-11 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2009150255A2 (en) 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
JP5581323B2 (ja) 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2388594A1 (en) 2010-05-17 2011-11-23 Roche Diagnostics GmbH GDF-15 based means and methods for survival and recovery prediction in acute inflammation
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
EP2506015A1 (en) 2011-04-01 2012-10-03 Universität Regensburg A prognostic and therapeutic signature for malignant melanoma
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
HRP20191326T1 (hr) 2012-09-26 2019-11-01 Univ Wuerzburg J Maximilians Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15)
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2014151026A1 (en) 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP3470848A3 (en) 2014-01-28 2019-05-22 Roche Diagnostics GmbH Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
MX385194B (es) 2014-02-21 2025-03-14 Nektar Therapeutics India Pvt Ltd Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
LT3653644T (lt) 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
EP3197493B1 (en) * 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3073268A1 (en) 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
CN108463246B (zh) 2015-10-02 2025-02-28 尤利乌斯·马克西米利安维尔茨堡大学 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR102621034B1 (ko) 2015-10-02 2024-01-03 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 면역 체크포인트 차단제를 이용한 치료의 임상적인 경과를 예측하기 위한 진단 마커로서의 gdf-15
HRP20250902T1 (hr) 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
WO2017189724A1 (en) * 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
JP7155403B2 (ja) * 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
EP4106815A4 (en) 2020-02-21 2024-04-24 The Children's Medical Center Corporation METHODS OF TREATING ASTHMA OR ALLERGIES
CN111393526B (zh) 2020-03-30 2022-04-12 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Abulizi P, Loganathan N, Zhao D, et al. Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by Lipopolysaccharide Sci Rep. 2017;7(1):1-10.
Bottner, Martina, Martin Laaff, Birgit Schechinger, Gudrun Rappold, Klaus Unsicker, and Clemens Suter-Crazzolara. 1999. "Characterization of the Rat, Mouse, and Human Genes of Growth/Differentiation Factor-15/Macrophage Inhibiting Cytokine-1 (GDF-15/MIC-1)." Gene 237 (1): 105-11.
Chung HK, Kim JT, Kim HW, et al. GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep. 2017;7(1):1-13. doi:10.1038/s41598-017-17574-w
Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47.
Emmerson, Paul J., Feng Wang, Yong Du, Qian Liu, Richard T. Pickard, Malgorzata D. Gonciarz, Tamer Coskun, et al. 2017. "The Metabolic Effects of GDF15 Are Mediated by the Orphan Receptor GFRAL." Nature Medicine 23 (10): 1215-19. https://doi.org/10.1038/nm.4393.
Hodi FS, Ballinger M, Lyons B, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 Mar 20;36(9):850-858.
Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat Med. 2007;13(11):1333-1340. doi:10.1038/nm1677
Kempf, Tibor, Alexander Zarbock, Christian Widera, Stefan Butz, Anika Stadtmann, Jan Rossaint, Matteo Bolomini-Vittori, et al. 2011. "GDF-15 Is an Inhibitor of Leukocyte Integrin Activation Required for Survival after Myocardial Infarction in Mice." Nature Medicine 17 (5): 581-88. https://doi.org/10.1038/nm.2354.
Selby, Mark J., John J. Engelhardt, Robert J. Johnston, Li-Sheng Lu, Minhua Han, Kent Thudium, Dapeng Yao, et al. 2016. "Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology." Edited by Aamir Ahmad. PLOS ONE 11 (9): e0161779. https://doi.org/10.1371/journal.pone.0161779.
Tong S, Marjono B, Brown DA, et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet. 2004;363(9403):129-130. doi:10.1016/S0140-6736(03)15265-8
Tsai, Vicky W.W., Yasmin Husaini, Amanda Sainsbury, David A. Brown, and Samuel N. Breit. 2018. "The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases." Cell Metabolism 28 (3): 353-68. https://doi.org/10.1016/j.cmet.2018.07.018.
van den Boorn, Jasper G., and Gunther Hartmann. 2013. "Turning Tumors into Vaccines: Co-Opting the Innate Immune System." Immunity 39 (1): 27-37. https://doi.org/10.1016/j.immuni.2013.07.011.
Vaupel, Peter. 2004. "Tumor Microenvironmental Physiology and Its Implications for Radiation Oncology." Seminars in Radiation Oncology 14 (3): 198-206. https://doi.org/10.1016/j.semradonc.2004.04.008.
Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018;32(3):1537-49.
Welsh, John B., Lisa M. Sapinoso, Suzanne G. Kern, David A. Brown, Tao Liu, Asne R. Bauskin, Robyn L. Ward, et al. 2003. "Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum." Proceedings of the National Academy of Sciences 100 (6): 3410-15. https://doi.org/10.1073/PNAS.0530278100.
Wischhusen J, Melero I, and Fridman W. GDF-15: From Biomarker to Novel Targetable Immune Checkpoint. Front. Immunol. Accepted 23 Apr 2020. doi: 10.3389/fimmu.2020.00951.
Wollert KC, Kempf T, Giannitsis E, et al. An Automated Assay for Growth Differentiation Factor 15. J Appl Lab Med An AACC Publ. 2018;1(5):510-521. doi:10.1373/jalm.2016.022376.

Also Published As

Publication number Publication date
EP4243928A1 (en) 2023-09-20
WO2022101263A1 (en) 2022-05-19
EP4243928B1 (en) 2026-04-22
CA3200687A1 (en) 2022-05-19
US20260055172A1 (en) 2026-02-26
IL302646A (en) 2023-07-01
US12497447B2 (en) 2025-12-16
US20240043517A1 (en) 2024-02-08
AU2021376864A1 (en) 2023-06-29
US20250282858A1 (en) 2025-09-11
JP2023548430A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
US12497447B2 (en) Anti-GDF15 antibody and a dosage regimen for the treatment of cancer
EP3583125B1 (en) Albumin binding domain fusion proteins
JP2022535564A (ja) 多選択性タンパク質
BR112020023346A2 (pt) anticorpo capaz de se ligar a muc1 e seu uso, ácido nucleico, cassete ou vetor de expressão, célula hospedeira, conjugado, composição, e, métodos para aumentar a afinidade de ligação a muc1 de um anticorpo e para produzir um anticorpo com afinidade de ligação a muc1 aumentada
US11440959B2 (en) CD226 agonist antibodies
CN113301961A (zh) 给予抗tim-3抗体的方法
US20250320268A1 (en) Clinical dosing of sirp1a chimeric protein
EP4624493A1 (en) Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr
CN116848137A (zh) 抗gdf15抗体以及用于治疗癌症的给药方案
JP2024544972A (ja) Ｓｉｒｐ１ａ及びｃｄ４０ｌベースのキメラタンパク質
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
JP2021529777A (ja) 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
KR20240110556A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
CN118613280A (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
CA3217833A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
US20250304673A1 (en) Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer
US20260042817A1 (en) Pet tracer for detection of transforming growth factor beta
KR20240022608A (ko) 항-tgf-베타 항체 제형 및 이의 용도
WO2024173352A2 (en) Methods of treating cancer with a sirp1a-based chimeric protein
CN119562830A (zh) 抗体组合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230609

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240827

Comment text: Request for Examination of Application